News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Eisai Company, Ltd. (ESALY.PK) Receives Approval to Market Anticancer Agent Halaven® in Australia



9/10/2012 9:59:04 AM

Tokyo, Sept 7, 2012 - (JCN Newswire) - Eisai Co., pharmaceutical sales subsidiary Eisai Australia Pty. Ltd. has received approval from the Australian Department of Health and Aging to market the anticancer agent Halaven(R) (eribulin mesylate) for the treatment of patients with locally advanced or metastatic breast cancer who have progressed after at least two chemotherapeutic regimens for advanced disease. Prior therapy should have included an anthracycline and a taxane unless patients were not suitable for these treatments.

Read at JCN Newswire


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES